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Abstract
Neuropathic pain is a chronic condition with potential deleterious effects on the patients quality of life.
Pharmacological treatment does not always bring the expected effects and it often brings about adverse
effects of the administered drugs. One of the causes for the intensification of pain is central sensitization.
Numerous trials, both experimental and clinical prove the effectiveness of NMDA receptor blockers in
preventing and diminishing central hypersensitivity and, as a result, diminishing the degree of pain sensa-
tions. Here we present a patient with neuropathic pain syndrome related to chemotherapy for Hodgkins
disease, in which by cyclical intravenous ketamine infusions, significant and long-lasting pain alleviation has
been achieved.
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Introduction
Neuropathic pain is usually caused by a primary
lesion of the nervous system. The frequency of neu-
ropathic pain occurrence is 1,5% of all patients with
chronic pains [1].
Neuropathic pain may appear due to a lesion of
peripheral nerves (for example by compression,
crushing or as a result of polyneuropathy), spinal
ganglions (compression, tumour). The same patho-
logical process in one patient may cause severe pain
and in another patient it may cause no reaction at
all. Factor that may influence this are the following:
the place of lesion, time, activating factor, coexist-
ence of other pathological processes, age, individu-
al inclinations and psychological factors [2].
Three mechanisms play an important role in the
formation of neuropathic pain  changes of elec-
tric irritability of the cell membranes of peripheral
neurons, changes of signal processing within the
dorsal horn and modification of central nervous sys-
tem response to pain stimuli.
Central sensitization  hypersensitivity of spinal
neurons and higher structures of the nervous system
 is one of the causes of pain intensification and it is
responsible for the chronic character of pain.
Central sensitization can at least for the great deal
be explained by activation of the glutaminergic system.
This causes the influx of calcium ions to the cell through
ionic channels of NMDA (N-methyl-D-aspartic acid) re-
ceptors, which in turn activate protein and tyrosine
kinases. As a result, proteins generating glutaminergic
receptors are getting phosphorylated and boost activi-
ty of these receptors. Calcium ions also activate phos-
pholipase, which launches the arachidonic acid cas-
cade. Consequently, the synthesis of prostaglandins that
lower the point of receptors sensitivity is escalated [3].
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Neuropathic pain is a condition that is very diffi-
cult to treat. No method that would be effective for
all types of neuropathic pain has been described so
far. Analgesics, such as paracetamol, non-steroidal
anti-inflammatory drugs and even opioids frequent-
ly do not help to alleviate the pain. The International
Association for the Study of Pain suggests interdis-
ciplinary treatment of patients with chronic pain,
which also includes neuropathic pain. Numerous tri-
als, both experimental and clinical prove the effec-
tiveness of NMDA receptor blockers in preventing
and diminishing central hypersensitivity and, as a
result, diminishing the degree of pain sensations
[46]. The drugs that are administrated are non-
specific blockers of the NMDA receptor, such as:
ketamine, dextromethorphan, memantine and
amantadine. What is more, NMDA inhibitors dimin-
ish opioid-induced hyperalgesia [7] and ketamine is
the most popular drug that is used in the prevention
of increasing opioid tolerance [8].
This study discusses the case of a patient with an
iatrogenic neuropathic pain, probably induced dur-
ing chemotherapy against Hodgkins disease, in
which by means of cyclical intravenous infusions of
ketamine, significant and long-lasting pain allevia-
tion has been achieved.
Case description
In 1993 a man at the age of 55 was diagnosed
with Hodgkins disease type III MC (Mixed cellulari-
ty). The patient underwent chemotherapy accord-
ing to MOPP scheme (chlormethine, vincristine, pro-
carbazine, prednizone), which resulted in total re-
mission. In June 1994 the patient started to com-
plain about pain in right shoulder, which intensified
a year later. The pain was of a paroxysmal character,
prickly, burning, radiating along the shadow towards
the hand. For this reason the patient was temporari-
ly taking non-steroidal anti-inflammatory drugs (di-
clofenac), which alleviated the pain. In 1997 the
doctors diagnosed a relapse of Hodgkins disease.
The patient was administered a second line chemo-
therapy according to the scheme MOPP/ABV  adri-
amycin, bleomycin, vinblastine, dacarbazine since
August 1998. Since then until now the patient has
been under the supervision of oncology clinic  no
relapse of the disease has been diagnosed. In 1998
after chemotherapy the shoulder pain of the same
character as before, but much stronger was accom-
panied by paresis of the pars flaccida of right upper
limb. Due to pain symptoms the patient was admin-
istered first non-steroidal anti-inflammatory drugs,
and in 1999 because of pain intensity escalation,
the doctors included also tramadol (3 × 50 mg)
joined with miorelaxants (baclofen) to the treatment.
In 2000 the doctors added amitryptyline 50 mg/
night and tetrazepam 15 mg/night to tramadol and
this significantly alleviated the pain. Such a combi-
nation of drugs in some patients may cause sero-
toninergic syndrome. In this case however, no alarm-
ing symptoms were observed. After several months,
the patient discontinued amitryptyline on his own
and a psychiatrist that he consulted with later add-
ed mianserine 15 mg/night. In 2001 the patient was
sent to Neurological Clinic due to further escalation
of pain. Apart from a significant escalation of tear-
ing paroxysmal pain, also periodical lividity of upper
limb appeared. Nuclear magnetic resonance did not
show any pathologic changes in the brachial plexus,
spinal cord and spinal channel in the cervical part.
The diagnose suggested neuropathic pain syndrome
probably connected to iatrogenic lesion of brachial
plexus after chemotherapy. The doctors tried to ad-
minister gabapentin (Neurontin), however the pa-
tient did not tolerate it. The patient was on sodium
valproate, initialy in the dose of 2 × 300 mg and
then 2 × 500 mg, paracetamol and tramadol when
pain appeared. In 2003 the patient was diagnosed
with diabetes treated with oral drugs (glipizide).
Since 2002 the man was also a patient of Pain Treat-
ment Clinic, where (13 times during 5 years) epidu-
ral blocks were conducted on the level C5C6, C6
C7 by administration of 80 mg of polcortolon, bra-
chial plexus blocks with 0.25 % of bupivacaine and
right C6 root block. This treatment, according to the
patient caused alleviation of pain for maximum of
23 weeks after each session.
 Due to the escalation of pain, that did not de-
crease even after sodium valproate dose increase up
to 2 × 600 mg and administration of paracetamol 3
× 1 g and 50 mg tramadol when pain appeared
(the patient did not tolerate greater doses of this
drug), the patient was kept on the Ward of Palliative
Care, where he was given continuous intravenus
ketamine infusions in growing doses from 100 to
500 mg a day, for 5 days. In order to prevent psy-
chomimetic symptoms ketamine was administered
with midazolam influsions 5 mg a day.
In the beginning of his stay in the hospital, the
patient assessed his pain for 8 in a scale of 11. The
pain was lowered already after one day of ketamine
administration. When the patient was leaving the
hospital, he assessed his pain as 2/10. During the
hospitalization inflammatory reaction appeared in
the place of ketamine infusion. The patient came to
the hospital again after 35 days. He claimed that the
pain remained at the level 34/10 for about 3 weeks
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and then begun to increase up to 7/10. Ketamine
was administered again in increasing doses with
midazolam and 25 mg of hydrocortisone. The in-
flammatory reaction appeared again, but it was not
that strong. Again the pain decreased significantly.
The patient was hospitalized 7 times at an average
interval between hospitalizations of 55 days. During
the following ketamine infusions hydrocortisone was
administered in the 50 mg dose and then 100 mg
dose, which prevented inflammatory reactions. The
inflammatory reaction was the only adverse effect
of ketamine observed in this patient. The doctors
introduced a modification of coanalgesics, adding
fluoxetine, initially in a dose of 10 mg/d and later on
20 mg/d and discontinuing sodium valproate, which
was replaced with gabapentin 3 × 300 mg, which
this time caused no side effects. This modification
did not cause any significant alleviation of pain.
Only the repetitive ketamine infusions reduced the
pain for a period of 3 to 4 weeks. Due to intolerance
of tramadol, it was replaced by buprenorphine ad-
ministered sublingually 3 × 0.2 mg. Neither this
drug reduced the pain significantly according to the
patient. During the last hospitalization the pain was
reduced from 8/10 in the beginning of treatment to
3/10 when the patient was leaving the hospital.
Discussion
Ketamine is a derivative of phencyclidine. The
available preparations are: a racemic mixture and
much more expensive, but much more related to
NMDA receptor, four times stronger analgesic and
with much less adverse effects enantiomer S [911].
No oral preparation is available but diluted inject-
able fluid of ketamine are also administered orally.
In Poland ketamine is registered only as a drug
used in anesthesiology, as a component of com-
pound anesthesia and very rarely as an independent
anesthetic drug.
Ketamine is a strong blocker of NMDA receptors
[12]. It integrates by a calcium channel with the
point of phencyclidine bond, when the channels are
open and active [13]. The bonding of ketamine and
NMDA receptor prevents the bonding of glutamate
secreted by pain synapses in this location. The drug
also integrates with another point of bonding, lo-
cated within the membrane, where the channel does
not need to be open, and this way the frequency of
channels openings is reduced [14]. Ketamine also
inhibits noradrenaline reuptake. This has antidepres-
sant effect even after a single intravenous dose. This
effects appears 2 hours after administration and
lasts up to one week. The immediate anti-depressive
effect may be connected to the direct interaction
with the glutaminergic system but not with dopam-
ine and serotonin metabolism which is observed with
traditional anti-depressants [15].
Ketamine brings the first effect after one minute
if administrated intravenously. In case of intramus-
cular infusion  after 5 minutes. Due to the short
time of action  from 30 min to 2 hours if adminis-
tered intramuscularly  it is usually administered
with a continuous subcutaneous or intravenous in-
fusion. In anesthesiology it is used in doses 0.52
mg/kg body weight i.v., in repetitive doses from 1/4
to full initial dose every 515 min i.m. 510 mg/kg
body weight or continuous i.v. 26 mg/kg body
weight/h. These doses are much higher than those
used in the case described above.
Ketamine is water and lipid-soluble. Bioavailabil-
ity 23% and 32% after oral and sublingual adminis-
tration, respectively [16]. The effect seems to be
correlated with the concentration of a metabolite
 norketamine, which has analgesic properties of
1/51/3 of the strength of ketamine. After oral ad-
ministration norketamine concentrations exceeds 4
times the concentration of ketamine, therefore, this
metabolite may significantly contribute to the total
analgesic effect. Norketamine undergoes hydroxila-
tion and is excreted with urine. However, there are
no records of intensified adverse effects in patients
with renal failure, in which metabolite accumula-
tion could occur [11].
Adverse effects appear in about 40% of patients
and they are more often observed after subcutane-
ous than oral administration. Most often appearing
were psychomotor symptoms (psychomotor slow-
down, dysphoria, euphoria, hallucinations), hyper-
tension, tachycardia, blurred vision, nystagmus, rav-
ing, dizziness. A very frequent side-effect of the drug
in case of intravenous infusion is cutaneous reaction
(focal lymphangitis) [17]. However, when ketamine
was administered in sub-anesthetic doses usually
no or minor effects of psychomotor incitement are
observed [18]. Nevertheless, even the patients who
exhibit symptoms such as hallucinations often de-
cide to continue the drug because of significant
effect on pain [19]. At the same time, administra-
tion of ketamine along with benzodiazepines effec-
tively prevents psychomotor symptoms [20].
The available data suggests that ketamine is ef-
fective as an auxiliary drug for morphine that signif-
icantly improves the analgesic effect in patients with
neoplasms [21]. In sub-anaesthetic doses ketamine
can be used for diminishing the dosage of opioids
and reduction of their side-effects [22]. It has been
proven that ketamine is useful as coanalgesic in cas-
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es of neuropathic pain on animals, volunteers and
in small clinic trials [6, 2325]. The effects of ket-
amine seem to be more significant in patients with
neuropathic pain which has lasted for less than 5
years [26]. However, its effectiveness has not been
proven in methaanalysis due to insufficient number
of randomized trials all with small number of evalu-
able patients [17]. In most trials with ketamine, this
drug was most often used together with morphine.
Only in few cases the trials included hydromorphone,
diacetylmorphine or combinations of these drugs.
Good effects of ketamine were also reported in pa-
tients with phantom pains [27]. It has been con-
firmed that transitory administration of ketamine
can bring long-lasting effects  alleviation of pain
lasting even for several weeks [2831]. In patients
treated with opioids due to limb pain related to
ischemia, a single four-hours intravenous ketamine
infusion in a dose of 0.6 mg/kg lowered the demand
for opioids during a weeks observation [29]. In pa-
tients with cancer, subcutaneous infusion of ket-
amine in a dose 100500 mg/day for 35 days result-
ed in reduction of pain by 67%, and continuous in-
travenous infusions repeated every month in a dose
of 100 mg/d for 2 days helped to reduce the dose of
opioids in 70% of patients [30]. Similarly, in patients
taking opioids, examined after 4 months, a beneficial
effect was reported after 2 days ketamine infusions
in a dose of 0.5 mg/kg/day [31]. In another trial, in
patients with neoplasm and neuropathic pain assessed
around 6/11, taking maximum tolerated doses of
morphine, amitriptyline, sodium valproate or a com-
bination of these drugs after an oral administration
of ketamine in a dose of 0.5 mg/kg 3 times a day, in 7
patients the pain reduced by 3 points in the scale of
11 points. These patients, however, were taking ket-
amine for a long time, therefore significant side ef-
fects were observed  4 patients had nausea, 2 loss
of appetite, 2 drowsiness [32]. The effectiveness of
ketamine administered intravenously or orally has
been proven in controlled trials [33] and case de-
scriptions [34]. Currently, the Center in Edinburgh is
conducting a double blind randomized trial of s-ket-
amine versus placebo in patients with neoplasm and
neuropathic pain. The trial is supposed to be finished
by the end of the year 2008 [35].
The case described in this case report supports
the idea that ketamine is a precious drug for pa-
tients with neuropathic pain that is resistant to oth-
er pharmacological methods of pain treatment. Ket-
amine was administered when treatment with anal-
gesics and coanalgesics despite numerous trials of
drugs rotation along with invasive treatment had
not come up to the expectations.
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